Blog
RSS FeedPosted by Michael Wonder on 16 Nov 2018
ICER issues final report on long-term prophylaxis for hereditary angioedema, provides policy recommendations to improve cost-effectiveness
15 November 2018 - Cost-effectiveness and coverage considerations hinge on the frequency and intensity of attacks. ...
Posted by Michael Wonder on 23 Aug 2018
ICER releases draft evidence report on long-term treatments for prevention of hereditary angioedema attacks
23 August 2018 - Public comment period now open until 20 September; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 12 Apr 2018
ICER posts draft scoping document on therapies for prevention of hereditary angioedema attacks
12 April 2018 - Document open to public comment until 2 May 2018; report expected to review lanadelumab (Shire), and C1 ...
Posted by Michael Wonder on 26 Mar 2018
ICER to assess therapies for hereditary angioedema in upcoming assessment
23 March 2018 - Review will be subject of October CTAF meeting; open input now being accepted until 9 April. ...
Posted by Michael Wonder on 11 Sep 2017
Institute for Clinical and Economic Review posts draft scoping document to guide review of emicizumab for haemophilia A
11 September 2017 - Document open to public comment until 29 September 2017. ...